Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Yinglei Gao"'
1
Akademický článek
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer
Autor: Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen
Publikováno v: Cancer Biology & Medicine, Vol 19, Iss 8, Pp 1172-1192 (2022)
Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6. Because of the important roles of HDACs in lung cancer development and th
Externí odkaz: https://doaj.org/article/129d5544b083412c884b8806ba845ad2
Zobrazit plný text záznamu
2
Akademický článek
Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Autor: Yuxiang Wang, Xian Li, Xueling Liu, Yi Chen, Chunhao Yang, Cun Tan, Bobo Wang, Yiming Sun, Xi Zhang, Yinglei Gao, Jian Ding, Linghua Meng
Publikováno v: Cancer Biology & Medicine, Vol 16, Iss 1, Pp 66-83 (2019)
Objective Activating KRAS mutations are the most common drivers in the development of non-small cell lung cancer (NSCLC). However, unsuccess of treatment by direct inhibition of KRAS has been proven. Deregulation of PI3K signaling plays an important
Externí odkaz: https://doaj.org/article/e333f50569794264bdd828f1bc042697
Zobrazit plný text záznamu
3
Akademický článek
Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study
Autor: Peng Wei, Bo Liu, Ruifeng Wang, Yinglei Gao, Lanlan Li, Yuchi Ma, Zhiwei Qian, Yuelei Chen, Maosheng Cheng, Meiyu Geng, Jingkang Shen, Dongmei Zhao, Jing Ai, Bing Xiong
Publikováno v: Acta Pharmaceutica Sinica B, Vol 9, Iss 2, Pp 351-368 (2019)
Genomic alterations are commonly found in the signaling pathways of fibroblast growth factor receptors (FGFRs). Although there is no selective FGFR inhibitors in market, several promising inhibitors have been investigated in clinical trials, and show
Externí odkaz: https://doaj.org/article/845aa42b2d4e4aab8ec6e2b40986655e
Zobrazit plný text záznamu
5
Data from Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Autor: Meiyu Geng, Jian Ding, Jingkang Shen, Bing Xiong, Yuchi Ma, Yinglei Gao, Yiming Sun, Yi Su, Xinying Yang, Yanyan Shen, Yong Xi, Yinchun Ji, Xia Peng, Yi Chen, Jing Ai
Because the receptor tyrosine kinase c-Met plays a critical role in tumor growth, metastasis, tumor angiogenesis, and drug resistance, the c-Met axis represents an attractive therapeutic target. Herein, we report the first preclinical characterizatio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3c1f8f80a5b5dd25ca12a3e745b6a72
https://doi.org/10.1158/1535-7163.c.6538083.v1
Zobrazit plný text záznamu
7
Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation
Autor: Qianqian Shen, Yinglei Gao, Shulei Zhu, Wei Lu, Lei Wang, Yanfen Fang, Yi Chen
Publikováno v: Journal of Medicinal Chemistry. 63:5421-5441
Herein, a series of HSP90 inhibitor-SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accumulation of SN38 via extracellular HSP90 (eHSP90)-med
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dde90e1110f7d3733eb4bef56df791c
https://doi.org/10.1021/acs.jmedchem.0c00305
Zobrazit plný text záznamu
8
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
Autor: Xia Peng, Meiyu Geng, Qi Wang, Xin Wang, Lin Chen, Yuchen Jiang, Zuhao Guo, Yue-Lei Chen, Yinglei Gao, Danqi Chen, Yang Dai, Huanyu Shi, Jingkang Shen, Yinchun Ji, Bing Xiong, Jing Ai
Publikováno v: European Journal of Medicinal Chemistry. 163:671-689
Although lung adenocarcinoma patients have benefited from the development of targeted therapy, patients with lung squamous cell carcinoma (SqCC) have no effective treatment due to the complexity and heterogeneity of the disease. Therefore, basing on
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f853a4678d669eb5f71c6567558f5d0d
https://doi.org/10.1016/j.ejmech.2018.12.015
Zobrazit plný text záznamu
9
Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study
Autor: Yuchi Ma, Meiyu Geng, Peng Wei, Bing Xiong, Dongmei Zhao, Lanlan Li, Maosheng Cheng, Jing Ai, Zhiwei Qian, Yinglei Gao, Jingkang Shen, Yue-Lei Chen, Ruifeng Wang, Bo Liu
Publikováno v: Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 9, Iss 2, Pp 351-368 (2019)
Genomic alterations are commonly found in the signaling pathways of fibroblast growth factor receptors (FGFRs). Although there is no selective FGFR inhibitors in market, several promising inhibitors have been investigated in clinical trials, and show
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3397f859ac56df71abaab02a4d167d4f
http://europepmc.org/articles/PMC6437634
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje